Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-22
2007-05-22
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S362000
Reexamination Certificate
active
10502827
ABSTRACT:
4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)-Thieno(2,3-D)pyrimidine or a salt thereof is useful for the treatment of urinary incontinence.
REFERENCES:
patent: 5744474 (1998-04-01), Thor
patent: O 467 365 (1992-01-01), None
Chen, Hong-I (Sep. 1990) Evidence for the presynaptic action of 5-hydroxytryptamine and the involvement of purinergic innervation in the rabbit lower urinary tractBr. J. Pharmacol. 101:212-216.
Eguchi, Junichi et al. (Apr. 2001) “The anxiolytic-like effect of MCI-225, a selective NA reuptake inhibitor with 5-HT3receptor antagonism”Pharmacology, Biochemistry and Behavior68:677-683.
Eguchi, Junichi et al. (1997) “Pharmacological Profile of the Novel Antidepressant 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno-[2,3-d]pyrimidine Monohydrate Hydrochloride”Arzneimittel-Forschung/Drug Research47(II), 12, 1337-1347.
Espey, Mary Jane et al. (1998) “Serotonergic modulation of spinal ascending activity and sacral reflux activity evoked by pelvic nerve stimulation in cats”Brain Research798:101-108.
Espey, Mary Jane and John W. Downie (1995) “Serotonergic modulation of cat bladder function before and after spinal transaction”European Journal of Pharmacology287:173-177.
Database Biosis ′Online!, Wu Ying-Liang et al. “Effects of acute and chronic administration of MCI-225, a new selective moradrenaline reuptake inhibitor with 5-HT3 receptor blocking action, on extraceullar noradrenaline levels in the hypothalamus of stressed rats” Database accession No. PREV200000291518, abstract, Japanese Journal of Pharmacology, vol. 83, No. 1, May 2000 pp. 31-18.
Cavalla David
Gristwood Robert William
Arachnova Therapeutics Ltd.
Desai Rita
Saliwanchik Lloyd & Saliwanchik
LandOfFree
Use of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3823582